J Korean Neurosurg Soc.  2025 Jan;68(1):60-66. 10.3340/jkns.2024.0030.

Effect of Intraoperative Ventricular Opening on Recurrence Patterns Following Bis-Chloroethyl-Nitrosourea Wafer Implantation for Newly Diagnosed Glioblastoma

• Matsuda R
• Maeoka R
• Morimoto T
• Nakazawa T
• Tokuda N
• Kotsugi M
• Takeshima Y
• Tamura K
• Yamada S
• Nishimura F
• Park YS
• Nakagawa I

• KMID: 2562983
• DOI: http://doi.org/10.3340/jkns.2024.0030

Abstract

Objective
: To evaluate the effect of ventricular opening (VO) on recurrence patterns in patients with newly diagnosed glioblastoma (GBM) treated with bis-chloroethyl-nitrosourea (BCNU) wafer implantation.
Methods
: This single-center retrospective study included 40 patients with newly diagnosed GBM who received BCNU wafer implantation after tumor resection between March 2013 and February 2022. The patients were categorized into two groups based on whether VO occurred during the GBM resection. While 18 patients had VO, 22 did not have VO. In cases with VO, the ventricular wall defect is closed with gelatin or oxidized regenerated cellulose and fibrin glue before BCNU wafer implantation. Recurrence patterns—classified as local, diffuse, distant, or multifocal—and time to recurrence were compared between patients with and without VO.
Results
: The median follow-up period for the entire cohort was 32.2 months (interquartile range, 16.7–38 months). Median survival time was comparable between patients with VO and patients without VO (38 vs. 26 months, p=0.53). Recurrence occurred in 31/40 patients (77.5%) in entire cohort. The incidence of recurrence was comparable between patients with VO and patients without VO (14 [77.8%] vs. 17 [77.3%], p=1.0). No significant differences were seen between the two groups in time to recurrence (p=0.59) or recurrence patterns (p=0.35).
Conclusion
: Ventricular opening during surgery with BCNU wafer implantation does not seem to influence the recurrence patterns. Ventricular opening does not induce distant recurrence if appropriate ventricular closure is performed.

Keyword

Carmustine; Gliadel; Glioblastoma; Ventricles; Recurrence

Figure

• 

  Fig. 1. Survival analysis. A : Kaplan-Meier curves of overall survival of the entire cohort of patients with newly diagnosed GBM. B : Overall survival of patients with VO (blue line) and without VO (black line) C : Overall survival of patients with VO and BCNU wafer implantation (blue line) and patients with VO and without BCNU wafer implantation (black line). VO : ventricular opening, BCNU : bis-chloroethyl-nitrosourea, GBM : glioblastoma.

Reference

References

1. Bettag C, Hussein A, Sachkova A, Bock HC, Mielke D, Rohde V, et al. Implantation of Carmustine wafers after resection of malignant glioma with and without opening of the ventricular system. J Neurooncol. 153:519–525. 2021.

2. Bodell WJ, Rupniak HT, Rasmussen J, Morgan WF, Rosenblum ML. Reduced level of DNA cross-links and sister chromatid exchanges in 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant rat brain tumor cells. Cancer Res. 44:3763–3767. 1984.

3. Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet. 345:1008–1012. 1995.

4. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 40:373–383. 1987.

5. Chowdhary SA, Ryken T, Newton HB. Survival outcomes and safety of carmustine wafers in the treatment of high-grade gliomas: a meta-analysis. J Neurooncol. 122:367–382. 2015.

6. Dörner L, Mustafa A, Rohr A, Mehdorn HM, Nabavi A. Growth pattern of tumor recurrence following bis-chloroethylnitrosourea (BCNU) wafer implantation in malignant glioma. J Clin Neurosci. 20:429–434. 2013.

7. Giese A, Kucinski T, Knopp U, Goldbrunner R, Hamel W, Mehdorn HM, et al. Pattern of recurrence following local chemotherapy with biodegradable carmustine (BCNU) implants in patients with glioblastoma. J Neurooncol. 66:351–360. 2004.

8. Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 48:452–458. 2013.

9. Lim M, Weller M, Idbaih A, Steinbach J, Finocchiaro G, Raval RR, et al. Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter. Neuro Oncol. 24:1935–1949. 2022.

10. Matsuda R, Maeoka R, Tokuda N, Nakazawa T, Morimoto T, Kotsugi M, et al. Intraoperative ventricular opening has no effect on complication development following BCNU wafer implantation for malignant glioma. World Neurosurg. 171:e707–e713. 2023.

11. Ohnishi T, Yamashita D, Inoue A, Suehiro S, Ohue S, Kunieda T. Is interstitial chemotherapy with carmustine (BCNU) wafers effective against local recurrence of glioblastoma? A pharmacokinetic study by measurement of BCNU in the tumor resection cavity. Brain Sci. 12:567. 2022.

12. Omuro A, Brandes AA, Carpentier AF, Idbaih A, Reardon DA, Cloughesy T, et al. Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: an international randomized phase III trial. Neuro Oncol. 25:123–134. 2023.

13. Piper RJ, Senthil KK, Yan JL, Price SJ. Neuroimaging classification of progression patterns in glioblastoma: a systematic review. J Neurooncol. 139:77–88. 2018.

14. Reardon DA, Brandes AA, Omuro A, Mulholland P, Lim M, Wick A, et al. Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial. JAMA Oncol. 6:1003–1010. 2020.

15. Reardon DA, Kim TM, Frenel JS, Simonelli M, Lopez J, Subramaniam DS, et al. Treatment with pembrolizumab in programmed death ligand 1-positive recurrent glioblastoma: results from the multicohort phase 1 KEYNOTE-028 trial. Cancer. 127:1620–1629. 2021.

16. Ricciardi L, Manini I, Cesselli D, Trungu S, Piazza A, Mangraviti A, et al. Carmustine wafers implantation in patients with newly diagnosed high grade glioma: is it still an option? Front Neurol. 13:884158. 2022.

17. Shibahara I, Miyasaka K, Sekiguchi A, Ishiyama H, Inukai M, Yasui Y, et al. Long-term follow-up after BCNU wafer implantation in patients with newly diagnosed glioblastoma. J Clin Neurosci. 86:202–210. 2021.

18. Shimato S, Nishizawa T, Ohshima T, Imai T, Goto S, Yamamoto T, et al. Patterns of recurrence after resection of malignant gliomas with BCNU wafer implants: retrospective review in a single institution. World Neurosurg. 90:340–347. 2016.

19. Sonoda Y, Shibahara I, Matsuda KI, Saito R, Kawataki T, Oda M, et al. Opening the ventricle during surgery diminishes survival among patients with newly diagnosed glioblastoma treated with carmustine wafers: a multi-center retrospective study. J Neurooncol. 134:83–88. 2017.

20. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 352:987–996. 2005.

21. Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA. 318:2306–2316. 2017.

22. Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol. 5:79–88. 2003.

23. Xiao ZZ, Wang ZF, Lan T, Huang WH, Zhao YH, Ma C, et al. Carmustine as a supplementary therapeutic option for glioblastoma: a systematic review and meta-analysis. Front Neurol. 11:1036. 2020.